Ziping Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ziping Li has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Fujing Zhang
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
2 shared publicationsXianghong Jin
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
2 shared publicationsBohan Yang
Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
1 shared publication- Hao Zhou
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
1 shared publication Haolong Li
Department of Medical Laboratory Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing China
1 shared publicationHuiwen He
Department of Hematology, Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China
1 shared publication
Latest Publications
- Open Access
- 26 January 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-10
Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab
Immunotherapy is a significant risk factor for severe COVID-19 in multiple myeloma (MM) patients. Understanding how immunotherapies lead to severe COVID-19 is crucial for improving patient outcomes. Human protein microarrays were used to examine the expression of 440 protein molecules in MM patients treated with bispecific T-cell engagers (BiTe) (n = 9), anti-CD38 monoclonal antibodies (mAbs) (n = 10), and proteasome inhibitor (PI)-based regimens (n = 10). Differentially expressed proteins (DEPs) were identified and analyzed using bioinformatics. BiTe therapy was associated with a higher incidence of severe COVID-19. We identified 21 and 29 DEPs between BiTe and anti-CD38 mAbs group, and BiTe and PI-based group, respectively, along with 25 DEPs between the anti-CD38 and PI groups. Principal component analysis and clustering showed distinct protein expression profiles between the BiTe and PI groups. Gene Ontology (GO) analysis revealed that DEPs between the BiTe and PI groups were related to cytokine activity and leukocyte migration. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that these DEPs were enriched in cytokine-cytokine receptor interaction and JAK-STAT signaling pathways. Leukemia inhibitory factor (LIF) is the most correlated with other DEPs and thus may play a key role in both enriched pathways, and the level of LIF protein was highest in the BiTe group. BiTe therapy is linked to a higher risk of severe COVID-19 due to an inflammatory cytokine storm, with LIF and the JAK-STAT pathway playing key roles. Targeting LIF and JAK-STAT pathway may help reduce severe COVID-19 in MM patients treated with BiTe.
- 26 January 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-10
Open AccessElevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab
Immunotherapy is a significant risk factor for severe COVID-19 in multiple myeloma (MM) patients. Understanding how immunotherapies lead to severe COVID-19 is crucial for improving patient outcomes. Human protein microarrays were used to examine the expression of 440 protein molecules in MM patients treated with bispecific T-cell engagers (BiTe) (n = 9), anti-CD38 monoclonal antibodies (mAbs) (n = 10), and proteasome inhibitor (PI)-based regimens (n = 10). Differentially expressed proteins (DEPs) were identified and analyzed using bioinformatics. BiTe therapy was associated with a higher incidence of severe COVID-19. We identified 21 and 29 DEPs between BiTe and anti-CD38 mAbs group, and BiTe and PI-based group, respectively, along with 25 DEPs between the anti-CD38 and PI groups. Principal component analysis and clustering showed distinct protein expression profiles between the BiTe and PI groups. Gene Ontology (GO) analysis revealed that DEPs between the BiTe and PI groups were related to cytokine activity and leukocyte migration. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that these DEPs were enriched in cytokine-cytokine receptor interaction and JAK-STAT signaling pathways. Leukemia inhibitory factor (LIF) is the most correlated with other DEPs and thus may play a key role in both enriched pathways, and the level of LIF protein was highest in the BiTe group. BiTe therapy is linked to a higher risk of severe COVID-19 due to an inflammatory cytokine storm, with LIF and the JAK-STAT pathway playing key roles. Targeting LIF and JAK-STAT pathway may help reduce severe COVID-19 in MM patients treated with BiTe.
- 25 June 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (8) , 1500-1509
Impaired acute‐phase humoral immunity is the major factor predicting unfavorable outcomes in multiple myeloma patients with SARS ‐ CoV ‐2 Omicron variants outbreak infection
At the end of 2022, a huge tide of SARS‐CoV‐2 infection mainly Omicron BA.4/5 developed in China. Multiple myeloma (MM) patients suffered cancer deterioration and mortality from COVID‐19, yet profound analyses of Omicron variants‐induced immunity function are scarce. We presented a longitudinal study in 218 MM patients and 73 healthy controls (HCs), reporting the prognostic factors and dynamic humoral and cellular immune responses. Neutralizing antibody and interferon γ ELISpot assay of SARS‐CoV‐2 was tested at three time points: 2–4, 8–10, and 14–16 weeks after infections. Our data showed older age, active MM, relapsed/refractory MM (R/RMM), immunotherapy, comorbidity, and non‐vaccination were risk factors associated with hospitalization. Severe humoral immunity impairment within 2–4 weeks was especially seen in patients with unvaccinated, older age, immunotherapy, R/RMM and comorbidities, while T‐cell response was relatively intact. Although antibodies of Omicron variants reached positive levels in MM patients at 8–10 weeks, half lost effective antibody protection at 14–16 weeks. However, most seronegative patients (76.2% at 2–4 weeks, 83.3% at 8–10 weeks) could develop effective T‐cell response. Notably, the inactivated wild‐type vaccinated patients exhibited weaker humoral and cellular immunity only at 2–4 weeks, escalating to similar levels as those in HCs later. Our findings indicate impairment of humoral immunity at acute‐phase after infection is the major factor correlated with hospitalization. One‐month suspension of immune therapy is suggested to prevent serious infection. These results confirm the value of inactivated vaccine, but indicate the need for additional booster at 14–16 weeks after infection for high‐risk MM population.
- 25 June 2024
- Published by Wiley in International Journal of Cancer
- Vol. 155 (8) , 1500-1509
Impaired acute‐phase humoral immunity is the major factor predicting unfavorable outcomes in multiple myeloma patients with SARS ‐ CoV ‐2 Omicron variants outbreak infection
At the end of 2022, a huge tide of SARS‐CoV‐2 infection mainly Omicron BA.4/5 developed in China. Multiple myeloma (MM) patients suffered cancer deterioration and mortality from COVID‐19, yet profound analyses of Omicron variants‐induced immunity function are scarce. We presented a longitudinal study in 218 MM patients and 73 healthy controls (HCs), reporting the prognostic factors and dynamic humoral and cellular immune responses. Neutralizing antibody and interferon γ ELISpot assay of SARS‐CoV‐2 was tested at three time points: 2–4, 8–10, and 14–16 weeks after infections. Our data showed older age, active MM, relapsed/refractory MM (R/RMM), immunotherapy, comorbidity, and non‐vaccination were risk factors associated with hospitalization. Severe humoral immunity impairment within 2–4 weeks was especially seen in patients with unvaccinated, older age, immunotherapy, R/RMM and comorbidities, while T‐cell response was relatively intact. Although antibodies of Omicron variants reached positive levels in MM patients at 8–10 weeks, half lost effective antibody protection at 14–16 weeks. However, most seronegative patients (76.2% at 2–4 weeks, 83.3% at 8–10 weeks) could develop effective T‐cell response. Notably, the inactivated wild‐type vaccinated patients exhibited weaker humoral and cellular immunity only at 2–4 weeks, escalating to similar levels as those in HCs later. Our findings indicate impairment of humoral immunity at acute‐phase after infection is the major factor correlated with hospitalization. One‐month suspension of immune therapy is suggested to prevent serious infection. These results confirm the value of inactivated vaccine, but indicate the need for additional booster at 14–16 weeks after infection for high‐risk MM population.
- 26 May 2020
- Published by Wiley in British Journal of Haematology
- Vol. 190 (2) , 179-184
Delayed‐phase thrombocytopenia in patients with coronavirus disease 2019 (COVID‐19)
Summary: Coronavirus disease 2019 (COVID‐19) can affect the haematopoietic system. Thrombocytopenia at admission was prevalent, while late‐phase or delayed‐phase thrombocytopenia (occurred 14 days after symptom onset) is rare. This retrospective, single‐centre study screened 450 COVID‐19 patients and enrolled 271 patients at the Union Hospital, Wuhan, China, from January 25 to March 9, 2020. COVID‐19‐associated delayed‐phase thrombocytopenia occurred in 11·8% of enrolling patients. The delayed‐phase thrombocytopenia in COVID‐19 is prone to develop in elderly patients or patients with low lymphocyte count on admission. The delayed‐phase thrombocytopenia is significantly associated with increased length of hospital stay and higher mortality rate. Delayed‐phase nadir platelet counts demonstrated a significantly negative correlation with B cell percentages. We also provided and described bone marrow aspiration pathology of three patients with delayed‐phase thrombocytopenia, showing impaired maturation of megakaryocytes. We speculated that immune‐mediated platelet destruction might account for the delayed‐phase thrombocytopenia in a group of patients. In addition, clinicians need to pay attention to the delayed‐phase thrombocytopenia especially at 3–4 weeks after symptom onset.
- 26 May 2020
- Published by Wiley in British Journal of Haematology
- Vol. 190 (2) , 179-184
Delayed‐phase thrombocytopenia in patients with coronavirus disease 2019 (COVID‐19)
Summary: Coronavirus disease 2019 (COVID‐19) can affect the haematopoietic system. Thrombocytopenia at admission was prevalent, while late‐phase or delayed‐phase thrombocytopenia (occurred 14 days after symptom onset) is rare. This retrospective, single‐centre study screened 450 COVID‐19 patients and enrolled 271 patients at the Union Hospital, Wuhan, China, from January 25 to March 9, 2020. COVID‐19‐associated delayed‐phase thrombocytopenia occurred in 11·8% of enrolling patients. The delayed‐phase thrombocytopenia in COVID‐19 is prone to develop in elderly patients or patients with low lymphocyte count on admission. The delayed‐phase thrombocytopenia is significantly associated with increased length of hospital stay and higher mortality rate. Delayed‐phase nadir platelet counts demonstrated a significantly negative correlation with B cell percentages. We also provided and described bone marrow aspiration pathology of three patients with delayed‐phase thrombocytopenia, showing impaired maturation of megakaryocytes. We speculated that immune‐mediated platelet destruction might account for the delayed‐phase thrombocytopenia in a group of patients. In addition, clinicians need to pay attention to the delayed‐phase thrombocytopenia especially at 3–4 weeks after symptom onset.